Academic literature on the topic 'Proteine s1'

Biological pattern discovery problems are computationally expensive. A possible technique for reducing the time to perform pattern discovery is parallelization. Since each task in a biological pattern discovery application is usually time-consuming by itself, we might be able to use networks of workstations (NOWs) that communicate infrequently. Persistent Linda (PLinda) is a distributed parallel computing system that runs on NOWs and it automatically utilizes idle workstations (Anderson and Shasha, 1992; Jeong, 1996). This means that labs can do parallel pattern discovery without buying new hardware. We propose an acyclic directed graph structure, exploration dag (E-dag for short), to characterize computational models of biological pattern discovery applications. An E-dag can first be constructively formed from specifications of a pattern discovery problem; then an E-dag traversal is performed on the fly to solve the problem. When done in parallel, the process of E-dag construction and traversal efficiently solves pattern discovery problems. Parallel E-dag construction and traversal can be easily programmed in PLinda. Finding active motifs in sets of protein sequences and in multiple RNA secondary structures are two examples of biological pattern discovery. Before discussing the framework, we introduce these two applications and briefly describe their computational models. Consider a database of imaginary protein sequences D = {FFRR, MRRM, MTRM, DPKY, AVLG} and the query “Find the patterns P of the form *X* where P occurs in at least two sequences in D and the size of P |P| ≥ 2.” (X can be a segment of a sequence of any length, and * represents a variable length don’t care [VLDC].) The good patterns are *RR* (which occurs in FFRR and MRRM) and *RM* (which occurs in MRRM and MTRM). Pattern discovery in sets of sequences concerns finding commonly occurring subsequences (sometimes called motifs). The structures of the motifs we wish to discover are regular expressions of the form *S1 * S2 * ... where S1,S2,… are segments of a sequence, that is, subsequences made up of consecutive letters, and * represents a VLDC. In matching the expression *S1 * S2 * … with a sequence S, the VLDCs may substitute for zero or more letters in S.

Surface activation of the plasma systems involved with coagulation, fibrinolysis, renin formation and kinin generation involves factor XII (Hageman factor). This protein is a 76,000 dalton glycoprotein which circulates in plasma as an inactive form of a serine protease. A human liver cDNA coding for factor XII was used to screen a human genomic phage library. Two overlapping clones were isolated, XHXII27 and XHXII76, and contain the entire gene for human factor XII. The gene is 13.5 Kbp in length and consists of 14 exons and 13 introns. The transcriptional start site of the mRNA was determined

Introdução: Uma infecção por SARS-CoV-2 pode desencadear uma resposta imune excessiva, conhecida como tempestade de citocinas, que pode levar à falência de múltiplos órgãos e à morte. Objetivo: Analisar como o SARs-CoV-2 interfere na cascata de coagulação e como os anticoagulantes podem atuar sendo possíveis coadjuvantes no tratamento da COVID-19. Material e métodos: As buscas foram realizadas em bases de dados bibliográficas — SciELO, BIREME, LILACS. Incluiu-se artigos do período de maio de 2020 a dezembro de 2020, com delineamento experimental ou observacional, em Inglês, Português e Espanho